By the Top Tier Newswire AI Desk · October 6, 2026 at 10:15 AM ET · reviewed against 8 wire stories
MODERNA INC (MRNA) is down -6.70% in the latest session. Our newswire has captured 8 stories on MRNA across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna Inc (NASDAQ:MRNA) fell 6.70% to $190.07 in early trading as investor sentiment shifted following updates on a suspected pneumonic plague case in Russia. Earlier gains driven by outbreak-related speculation faded after health officials and the World Health Organization downgraded the risk level. The stock opened at $203.85 and peaked at $212.22 before retreating sharply, with volume already reaching 5.2 million shares, or 0.4 times the 3-month average.
What Happened
Initial enthusiasm for vaccine-related stocks surged after reports of a lab worker's death in Russia raised concerns about a potential pneumonic plague. Moderna and Novavax (NASDAQ:NVAX) both saw early gains, with Moderna rising as high as $212.22. However, as the day progressed, health authorities and the WHO clarified that the risk was low, leading to a reversal in sentiment. Moderna’s stock dropped sharply after 10:10 AM ET when it hit an intraday low of $189.28. The stock’s decline reflects the volatility of the sector, where news of disease outbreaks can rapidly shift market expectations.
What The Data Shows
The stock has traded between $22.28 and $208.90 over the past 52 weeks. Despite its recent 8.6% rise over the last eight sessions, Moderna remains unprofitable, with a trailing twelve-month net loss of $8.01 per share and a revenue decline of 27.6%. The stock has a beta of 1.11, indicating higher volatility than the broader market. Options activity has been mixed, with $18.0 million in call premium and $14.3 million in put premium traded in the last 36 hours. On the 52-week tape, the stock hit nine fresh 52-week highs and twelve fresh 52-week lows on October 6. Insider sales have continued, with five transactions totaling $49.2 million in the last 90 days.
What To Watch
Moderna is not scheduled to report earnings in the near term. Investors will likely monitor coverage breadth and options flows as key indicators of market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · today's session (5-min) · -6.30% vs prior close · updated 3:08 PM ETAI sentiment, last 36h · averaged over 8 stories · 59/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
5h ago24/7 Wall St.BEARISH 42General
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), since the company’s rally priced a government-purchase scenario that its product line doesn’t address. Novavax stock trades at $12.32, down 2% in morning […]
8h agoSeeking AlphaNEUTRAL 47General
Novavax, Moderna cool as WHO downplays plague-related death in Russia
Novavax (NVAX) stock and Moderna (MRNA) stock trade flat after WHO updates on a suspected pneumonic plague death in Russia. Read more here.
15h agoStocktwits NewsBULLISH 58General
NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.
19h agoStocktwits NewsBULLISH 67Product/PR
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
23h agoStocktwits NewsBULLISH 67General
MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns
Nasdaq said on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.
1d ago24/7 Wall St.BULLISH 67Product/PR
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.28, a move that stands well apart from its closest vaccine rivals and the broader sector. Checking […]
1d ago24/7 Wall St.BULLISH 68Product/PR
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Shares of Moderna (NASDAQ:MRNA) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly. In afternoon trading, Moderna stock has risen 8%, reaching $204.60, extending a sharp rerating tied to the melanoma program. That gain […]
1d agoThe FlyBULLISH 56General
Cboe data shows mixed options sentiment in Moderna with shares up 0.52%
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →